eastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning

Similar documents
The case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.

New Targets and Treatments for Follicular Lymphoma

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma

12 th Annual Hematology & Breast Cancer Update Update in Lymphoma

Mathias J Rummel, MD, PhD

The case for maintenance rituximab in FL

Open questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland

DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA

RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA

SEQUENCING FOLLICULAR LYMPHOMA

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma

Brad S Kahl, MD. Tracks 1-21

Update: Non-Hodgkin s Lymphoma

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe

MMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE

Patterns of Care in Medical Oncology. Follicular Lymphoma

Treatment Nodal Marginal Zone Lymphoma

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL

Targeted Radioimmunotherapy for Lymphoma

Low grade Non-Hodgkin Lymphoma: New Therapies & Updates

Rituximab in the Treatment of NHL:

FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?

Il trattamento del Linfoma Follicolare in prima linea

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

Managing patients with relapsed follicular lymphoma. Case

Jonathan W Friedberg, MD, MMSc

Notification to Implement Issued by pcodr: December 14, 2012

pan-canadian Oncology Drug Review Initial Clinical Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma August 30, 2018

Supplementary Appendix to manuscript submitted by Trappe, R.U. et al:

Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer

How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES

BENDAMUSTINE + RITUXIMAB IN CLL

Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!

EGFR inhibitors in NSCLC

Splenic marginal zone NHL: Update on biology and therapy. Jonathan W. Friedberg M.D., M.M.Sc.

Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma

Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009

Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System

CAR-T cell therapy pros and cons

Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012

Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective

MEETING SUMMARY ASH 2018, San Diego, USA

Clinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel

ASH POSTER: LYMRIT UPDATE

NASDAQ: TGTX Jefferies Healthcare Conference June 2015

CME Information. Y-ibritumomab tiuxetan to that of rituximab maintenance for patients with newly diagnosed follicular lymphoma (FL).

BTK Inhibitors and BCL2 Antagonists

R/R DLBCL Treatment Landscape

Biogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development

Model-based optimization of rituximab dosing regimen in follicular non-hodgkin lymphoma

Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant

Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta

Mantle cell lymphoma An update on management

Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma

Bcl-2 inhibition in NHL. Jonathan W. Friedberg M.D., M.M.Sc.

Idelalisib in the Treatment of Chronic Lymphocytic Leukemia

Constan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia

What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin

Emerging targeted therapies for follicular lymphoma A future without chemotherapy

Edith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes

ORIGINAL ARTICLE. Suresh Advani 1, Shubhadeep Sinha 2, Pankaj Thakur 3, Neetu Naidu 3, Sreenivas Chary 3, Ghanshyam Biswas 4, Vamsi Krishna Bandi 5

Disclosures WOJCIECH JURCZAK

Mantle Cell Lymphoma. A schizophrenic disease

The Use and Effectiveness of Rituximab Maintenance in Patients with Follicular Lymphoma Diagnosed Between 2004 and 2007 in the United States

Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University

Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?

To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors

Disclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida

Nuove opportunità di cura. Stefano Sacchi, Modena

Common disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,

B Kahl 1, M Hamadani 2, P Caimi 3, E Reid 4, K Havenith 5, S He 6, JM Feingold 6, O O Connor 7

Scottish Medicines Consortium

Follicular Lymphoma 2016:

TRANSPARENCY COMMITTEE OPINION. 8 November 2006

Radiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian

MEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER

Update: New Treatment Modalities

Immunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017

Updates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

INMUNOTERAPIA I. Dra. Virginia Calvo

International Conference on Malignant Lymphoma (ICML) June 14-17, 2017

Follicular Lymphoma: Updates and novel immune therapies

Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels

BTKi in MCL. Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth UK

Bendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service

DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA

Maintenance paradigm in non-squamous NSCLC

POST ICML Indolent lymphomas relapse treatment

Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer

Smoldering Myeloma: Leave them alone!

Radiotherapy in aggressive lymphomas. Umberto Ricardi

NHS England. Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer

Transcription:

Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning eastern cooperative oncology group

Background: Rituximab in Low Tumor Burden Indolent B-Cell Lymphoma Is Watch & Wait, until high tumor burden develops, the best strategy in the rituximab era? Single agent R is active and well tolerated in frontline CLL/SLL Hainsworth et al, J Clin Oncol 2003 Single agent R is active and well tolerated in frontline low tumor burden Follicular Lymphoma Colombat et al, Blood 2001 Can rituximab provide a low-risk treatment strategy which could delay the time to first chemotherapy?

E4402 RESORT: Rituximab Extended Schedule or Retreatment Trial Hypothesis: After initial rituximab therapy, extended scheduled dosing (Maintenance Rituximab - MR) will prolong disease control compared to retreatment dosing administered upon disease progression (Rituximab Retreatment - RR) Study rationale: Previously untreated, low tumor burden, indolent B- cell lymphoma is an ideal patient population to test this hypothesis Primary endpoint: Time to Treatment (Rituximab) Failure

ECOG 4402 (RESORT): A phase III randomized trial of rituximab in patients with low-tumor burden indolent NHL Induction Rituximab 375 mg/m 2 q wk 4 Restage, wk 12 CR or PR R A N D O M I Z E Maintenance Rituximab * 375 mg/m 2 q 3 mo Rituximab Retreatment at progression* 375 mg/m 2 q wk 4 *Continue until treatment failure: (exam q 3 mo, CT q 6 mo) No response to retreatment, or disease progression within 6 mo of R Initiation of cytotoxic therapy, or inability to complete therapy

E4402 Major Eligibility Indolent NHL Follicular grade 1 or 2 Small Lymphocytic MALT Marginal Zone nodal Marginal Zone splenic No prior lymphoma therapy Stage III or IV disease Measurable disease Low tumor burden as defined by GELF No tumor mass > 7cm Fewer than 3 nodal masses > 3 cm No system symptoms or B symptoms No splenomegaly greater than 16 cm by CT scan No risk of organ compression No leukemic phase No cytopenias

E4402 (RESORT) Objectives Primary To compare the Time to Treatment Failure (TTF) between the MR and the RR arms Secondary To compare time to first cytotoxic therapy (chemotherapy or radiation therapy) between the MR and the RR arms To compare QOL between the arms To compare toxicities between arms

E4402 (RESORT) Statistical Considerations 81% power to detect 36% reduction in the TTF hazard rate in FL patients Type I error 5% (two sided) Required 270 randomized FL patients The study included non-fl patients Stratification factors Age (< 60 vs > 60) Time from diagnosis (< 1 year vs > 1 year) DMC recommended release of study results at a planned interim analysis in Sept 2011

E4402 (RESORT) Results Activated Nov 2003 Closed to accrual Sep 2008 384 Follicular lymphoma Kahl et al, ASH 2011; ASCO/ASH Joint Session 2012 129 non-follicular lymphoma 55 Small lymphocytic (SLL) 71 Marginal zone (MZL) 3 Other 50 (39%) of non-fl responded to Induction rituximab 21 assigned to Retreatment Rituximab (RR) 29 assigned to Maintenance Rituximab (MR)

E4402 RESORT Trial: Response to Induction Rituximab by lymphoma subtype SLL Splenic MZL Extranodal MZL Nodal MZL Other B- cell Total n 55 5 38 28 3 129 ORR 12 (22%) 5 (100%) 14 (37%) 17 (61%) 2 (66%) 50 (39%) 1 CR/CRu 0 2 5 1 1 9 (7%) PR 12 3 9 16 1 41 (32%) SD 40 0 19 11 1 71 (59%) PD 2 0 1 0 0 3 (2%) 1 ORR in FL = 70% (p <.001)

Baseline Characteristics at Randomization RR (N=21) MR (N=29) Age 63 (47-86) 65 (39-85) Gender (M/F) 32/68% 52/48% PS (0/1) 86/14% 93/7% Stage III 27% 24% IV 73% 76% B2M elevated 64% 69%

Disease status at randomization RR (N=21) MR (N=29) CR/CRu 19% 17% PR 81% 83% Median follow up for time to event data: 4.3 years

Primary Endpoint: Time to Treatment Failure HR= 4.77, 95% CI, (1.78, 12.79)

Breakdown of Treatment Failure by Type Failure Type RR MR Total No response to R retreatment Disease progression <6mo Alternative therapy 2 NA 2 5 3 8 5 0 5 Adverse event 0 2 2 Complicating disease 1 3 4 Patient withdrawal 3 6 9 Other/unknown 0 1 1 Total 16 15 31

Time to First Cytotoxic Therapy

Treatment Information Analysis of # doses rituximab received, including the 4 induction doses Min Max Median Mean RR (n = 21) 4 12 4 6.0 MR (n = 29) 5 30 17 17.6

Toxicity Second malignancies 4 in RR arm 2 in MR arm (1 basal cell cancer) 6 (2 basal cell) among the non-randomized pts who received R x 4 only Two Grade 4 toxicities in MR arm Encephalopathy Neutropenia Deaths None

RESORT: Different Outcomes Observed for Follicular versus non-follicular Subtypes Higher response rates to R x 4 induction in FL vs non-fl CR/PR = 70% vs 39% (p <.001) ORR for non-fl: MZL = 51% vs SLL = 22% No TTF benefit was observed with MR in FL vs a significant benefit in non-fl A time to cytotoxic chemotherapy benefit was observed for MR in both FL and non- FL subtypes, with a greater difference for the non-fl * Kahl et al, ASH 2011 Late-Breaking Abstract #6; ASCO/ASH Joint Session, 2012

Time to Treatment Failure: Follicular Lymphoma vs Non-FL Subtypes Kahl et al, ASH 2011 LBA #6; ASCO/ASH Joint Session 2012

Time to First Cytotoxic Therapy: Follicular Lymphoma vs Non FL Subtypes Kahl et al, ASH 2011 LBA #6; ASCO/ASH Joint Session 2012

Summary In this study of previously untreated, low tumor burden non-follicular indolent B-cell lymphoma patients who achieved CR or PR to Rituximab x 4: Maintenance rituximab was superior to retreatment rituximab for the primary endpoint of time to treatment failure MR was also superior to RR for time to cytotoxic therapy At 3 years, no MR patient (vs 30% of RR) had received cytotoxic therapy MR patients received 3 x more R doses than RR

Conclusions If opting for Rituximab monotherapy in low- tumor burden indolent B-cell lymphoma patients: Follicular lymphoma Rituximab Retreatment is our recommended strategy in responding patients* Non-Follicular indolent lymphoma Maintenance Rituximab is an acceptable strategy in responding patients, although larger studies of the non-fl subtypes will be needed to verify these results * Kahl et al, ASH 2011 Late-Breaking Abstract #6; ASCO/ASH Joint Session, 2012

Future Directions Continuing to follow for endpoints of Overall survival Risk for transformation In depth quality of life analysis Biomarker analysis PKs Fc Receptor polymorphisms Microenvironment analysis via TMAs Gene expression profiling

Acknowledgements Co-authors ECOG coordinating center and statistical center CTSU Co-investigators Patients